BridgeBio Pharma Free Cash Flow 2018-2025 | BBIO
BridgeBio Pharma annual/quarterly free cash flow history and growth rate from 2018 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- BridgeBio Pharma free cash flow for the quarter ending September 30, 2025 was -390.55, a year-over-year.
- BridgeBio Pharma free cash flow for the twelve months ending September 30, 2025 was , a year-over-year.
- BridgeBio Pharma annual free cash flow for 2024 was $-0.522B, a 1.39% decline from 2023.
- BridgeBio Pharma annual free cash flow for 2023 was $-0.529B, a 24.68% increase from 2022.
- BridgeBio Pharma annual free cash flow for 2022 was $-0.424B, a 16.99% decline from 2021.
| BridgeBio Pharma Annual Free Cash Flow | |
|---|---|
| 2024 | -521.66 |
| 2023 | -529.03 |
| 2022 | -424.32 |
| 2021 | -511.18 |
| 2020 | -407.23 |
| 2019 | -256.23 |
| 2018 | -138.82 |
| 2017 | -40.95 |
| BridgeBio Pharma Quarterly Free Cash Flow | |
|---|---|
| 2025-09-30 | -390.55 |
| 2025-06-30 | -280.51 |
| 2025-03-31 | -199.24 |
| 2024-12-31 | -521.66 |
| 2024-09-30 | -326.29 |
| 2024-06-30 | -145.58 |
| 2024-03-31 | -220.23 |
| 2023-12-31 | -529.03 |
| 2023-09-30 | -403.77 |
| 2023-06-30 | -258.12 |
| 2023-03-31 | -144.33 |
| 2022-12-31 | -424.32 |
| 2022-09-30 | -330.27 |
| 2022-06-30 | -194.35 |
| 2022-03-31 | -161.49 |
| 2021-12-31 | -511.18 |
| 2021-09-30 | -374.75 |
| 2021-06-30 | -246.73 |
| 2021-03-31 | -152.73 |
| 2020-12-31 | -407.23 |
| 2020-09-30 | -308.68 |
| 2020-06-30 | -176.45 |
| 2020-03-31 | -88.40 |
| 2019-12-31 | -256.23 |
| 2019-09-30 | -178.28 |
| 2019-06-30 | -127.90 |
| 2019-03-31 | -59.57 |
| 2018-12-31 | |
| 2018-09-30 | -91.67 |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $12.538B | $0.222B |
| BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $29.293B | 9.90 |
| Dr Reddy's Laboratories (RDY) | India | $11.580B | 17.12 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.548B | 20.86 |
| Bausch Health Cos (BHC) | Canada | $2.455B | 1.74 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.212B | 8.73 |
| Taysha Gene Therapies (TSHA) | United States | $1.098B | 0.00 |
| Personalis (PSNL) | United States | $0.675B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.273B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.099B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.017B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |